LIPOSOME ENCAPSULATED ANTIGENS AS VACCINES FOR BRUCELLA ABORTUS AND FRANCISELLA TULARENSIS

PDF

Authors
  1. Cherwonogrodzky, W.
Corporate Authors
Defence Research Establishment Suffield, Ralston ALTA (CAN)
Abstract
From 30 August 1991 to 30 August 1995, DRES received a task from the Surgeon General's Office to develop a liposomal vaccine both to Brucella abortus and Francisella tularensis. Funding was $160,000 over these 4 years. Currently there is no vaccine for human use to the Brucella species. There is an effective attenuated vaccine to tularemia, Francisella tularensis live vaccine strain (LVS), but this bacterium can revert to a virulent form if cultural conditions are not followed as specified. A novel purified polysaccaride vaccine has been produced for B. abortus. Liposomal encapsulation was found not to be required for its effectiveness. Protection did not appear to be due to an antibody response, and indeed may be counter-indicative. The vaccine was protective for mice and guinea pigs against B. abortus and for swine against B. suis (hence it appears to offer broad protection). Single injections of 100 ug (lesser amounts were not tested) were found to be 100% protective for 25 kg swine challenged with virulent field strains of B. suis. A year later these swine were still protected a 75 kg person. Initially 15,000 human dose equivalents was to be prepared for research and a potential emergency supply. The final preparation was enough for 150,000 human equivalent doses. Due to a lack of containment facilities, the vaccine could not be tested for protection against cross-reactive pathogens (e.g. Francisella tularensis).
Keywords
Francisella tularensis
Date of publication
01 May 1995
Number of Pages
30
DSTKIM No
95-05071
CANDIS No
153783
Format(s):
Document Image stored on Optical Disk;Hardcopy

Permanent link

Document 1 of 1

Date modified: